Related Experiment Videos
99mTc-labeled mannosyl-neoglycoalbumin for sentinel lymph node identification.
Kyoko Takagi1, Tomoya Uehara, Emi Kaneko
1Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8675, Chiba, Japan.
Nuclear Medicine and Biology
|October 7, 2004
Summary
This study developed a new radiopharmaceutical, 99mTc-labeled mannosyl-neoglycoalbumin (NMA), for sentinel lymph node (SLN) identification. The novel tracer showed superior accumulation in SLNs compared to existing agents, offering improved diagnostic potential.
Area of Science:
- Nuclear Medicine
- Radiopharmaceutical Science
- Oncology Imaging
Background:
- Sentinel lymph node (SLN) biopsy is crucial for cancer staging.
- Existing radiotracers like 99mTc-labeled human serum albumin (HSA) have limitations, including rapid clearance from injection sites.
- There is a need for improved radiopharmaceuticals for accurate SLN identification.
Purpose of the Study:
- To prepare and evaluate 99mTc-labeled mannosyl-neoglycoalbumin (NMA) as a novel radiopharmaceutical for SLN identification.
- To compare the performance of [99mTc](HYNIC-NMA)(tricine)2 with existing agents ([99mTc](HYNIC-HSA)(tricine)2 and [99mTc]colloid) in a murine model.
- To investigate the factors influencing SLN accumulation of the novel tracer.
Main Methods:
- Conjugation of NMA with 6-hydrazinopyridine-3-carboxylic acid (HYNIC) and labeling with 99mTc.
- Subcutaneous injection of [99mTc](HYNIC-NMA)(tricine)2 in murine foot pads.
- Comparison of radioactivity levels in lymph nodes, injection site, and other tissues with control radiotracers at various time points.
Main Results:
- [99mTc](HYNIC-NMA)(tricine)2 demonstrated significantly higher radioactivity in the popliteal lymph node (SLN) compared to [99mTc](HYNIC-HSA)(tricine)2 and [99mTc]colloid.
- The novel tracer exhibited dose-dependent accumulation in the SLN, with increased distribution to blood, liver, and spleen at higher NMA doses.
- [99mTc]colloid showed decreased SLN accumulation with dilution, while injection site activity increased.
- Both [99mTc](HYNIC-NMA)(tricine)2 and [99mTc](HYNIC-HSA)(tricine)2 had similar injection site radioactivity levels.
Conclusions:
- The addition of macrophage binding function to HSA via mannosylation enhances selective radioactivity accumulation in SLNs.
- [99mTc](HYNIC-NMA)(tricine)2 is a promising radiopharmaceutical for SLN identification due to its high and selective SLN uptake without affecting elimination from the injection site.
- The number of colloidal particles and the molar dose of mannosylated compounds are critical for optimal SLN accumulation.